-
Becton, Dickinson and Company Acquires Edwards Lifesciences' Critical Care Business for $4.2 Billion
In a strategic move to expand its medical monitoring solutions, Becton, Dickinson and Company (BD) has announced the acquisition of Edwards Lifescienc...
2024-06-05 17:19 -
Summit Therapeutics Secures $200 Million Investment from Top Biotech Hedge Fund
In a significant boost, Summit Therapeutics, a clinical-stage biopharmaceutical company, has announced a $200 million investment from the renowned Bak...
2024-06-05 17:15 -
Groundbreaking Results for Carrelizumab in Late-Stage Esophageal Squamous Cell Carcinoma
The final analysis of the ESCORT-1st study revealed exceptional long-term outcomes for patients with advanced esophageal squamous cell carcinoma (ESCC...
2024-06-05 17:14 -
The Fate of the Used 'BAM-15 for Sale'
This article will take readers on a journey through the ups and downs of the second-hand "BAM-15 for sale" and explore related social issues along the...
2024-06-05 15:32 -
The Amazing Benefits of 'BAM-15 Supplement'
This article will delve deeper into the effects and status of "BAM-15 supplement" in today's society.
2024-06-05 15:26 -
'BAM-15 Dosage' Use with Caution
This article will explore the safety precautions of "BAM-15 dosage" usage, reminding everyone to be cautious and vigilant when using it.
2024-06-05 15:20 -
Astellas Resubmits Claudin18.2 Antibody Marketing Authorization Application
Recently, the pharmaceutical company Astellas announced that the U.S. Food and Drug Administration (FDA) has confirmed the resubmission of the Biologi...
2024-06-04 16:57 -
New Funding Rounds for 11 AI Pharmaceutical Companies in May
In May 2024, a total of 11 AI-driven pharmaceutical companies around the world raised new rounds of funding, amounting to approximately 2.021 billion ...
2024-06-04 16:54 -
The Top 20 Best-Selling Drugs Globally in Q1 2024
The pharmaceutical industry has continued to evolve, with the landscape shifting as new treatments emerge and existing drugs see changing fortunes.
2024-06-04 16:52 -
Gilead's $21 Billion Acquisition of Trodelvy Turns Bittersweet
In the world of biotech acquisitions, Gilead's $21 billion purchase of Immunomedics and its lead drug Trodelvy has become a topic of much discussion.
2024-06-03 17:32
Hot News
- BASF’s Big Restructuring: Cut... Sep 01, 2025
- German Chemical Industry Outpu... Sep 15, 2025
- DuPont Bids Farewell to Its Ar... Sep 02, 2025
- ExxonMobil Eyes $1 Billion Pet... Sep 16, 2025
- FDA Clears Sanofi’s Wayrilz (... Aug 31, 2025
Related Products
Related Producers
